You are here

Armodafinil Significantly Improves Wakefulness in Phase 3 Studies

WEST CHESTER, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that its Phase 3 studies of 150- and 250-milligram daily doses of NUVIGIL(TM) (armodafinil) in patients suffering from either excessive sleepiness associated with narcolepsy, shift work sleep disorder (SWSD) or obstructive sleep apnea/hypopnea syndrome (OSA/HS) show that the medication significantly improves wakefulness and the overall clinical condition of patients as compared to placebo. NUVIGIL is a single- isomer of the active pharmaceutical ingredient contained in PROVIGIL(R) (modafinil) Tablets [C-IV].

The 12-week, double-blind, randomized, placebo-controlled Phase 3 studies of approximately 1,000 patients included one study of excessive sleepiness in narcolepsy, one study in SWSD and two studies in OSA/HS. The primary endpoints in all studies were measures of objective sleep latency (Maintenance of Wakefulness Test or Multiple Sleep Latency Test) and the physician rating of Clinical Global Impression-Change. These primary endpoints are identical to those studied for the currently approved indications for PROVIGIL. In each study, patients treated with NUVIGIL showed a statistically significant improvement on both primary endpoints compared to placebo (all p values In these Phase 3 studies, NUVIGIL was generally well tolerated, with a safety profile consistent with that observed in other studies of PROVIGIL. The most common adverse effects observed included headache, nausea, dizziness, insomnia and anxiety.

The complete data on these four studies are expected to be presented at several major medical meetings in 2005, including the Associated Professional Sleep Societies meeting in June. Cephalon expects to file a New Drug Application for NUVIGIL on schedule with the U.S. Food and Drug Administration (FDA) this quarter.

"We expect to deliver a filing that highlights the safety and efficacy of NUVIGIL for these patient populations and demonstrates clinical improvements in fatigue and cognition, as well as a long duration of action without affecting the patient's normal sleep schedule," said Dr. Paul Blake, Senior Vice President, Clinical Research and Regulatory Affairs, at Cephalon.

Source: Cephalon, Inc.

Recent Headlines

Breast Cancer, Gastrointestinal Tumors Most Common Types
Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens